Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 30 September 2026
Artificial intelligence (AI) technologies to help detect prostate cancer on MRIStatus:In developmentProgramme:Health technology evaluationExpected publication date: 12 November 2026
Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 April 2027
Prostate cancer: diagnosis and management (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 17 December 2027
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 19 June 2026Expected publication date: TBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cancer case finding technologies to support early recognition of suspected cancer symptoms in primary care: early use assessmentStatus:In developmentProgramme:HealthTech guidanceExpected publication date: TBC